GlobeNewsWire
10 Jul 2026, 00:30 UTC · 1h ago
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
10 Jul 2026, 00:30 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Ryoncil generated US$115 million in net revenue for the full year ended June 30, 2026, exceeding initial projections. — Stronger-than-expected commercial launch and revenue generation for a primary product typically leads to a significant upward valuation of a biotech company.
+0.80Mesoblast's operational activities are now well-funded through revenue growth and a new five-year credit facility. — Reducing reliance on dilutive equity financing to fund operations is a major positive for shareholders and decreases bankruptcy risk.
+0.60Ryoncil is the only FDA-approved product for children under age 12 with steroid-refractory acute graft-versus-host disease. — Maintaining a monopoly position in a specific pediatric indication provides a secure moat and predictable revenue stream.
+0.40Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company reported strong net revenue for Ryoncil that exceeded initial projections and announced a strong capital position.
The company reported strong net revenue for Ryoncil that exceeded initial projections and announced a strong capital position.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
3h ago
